Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?

Cardiology

Volumn 92, Issue 2, 1999, Pages 99-105

  Chafin, Carol C ^a   Soberman, Judith E ^a   Demirkan, Kutay ^a   Self, Timothy ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Asthma; Myocardial infarction; blockers

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVANTOLOL; BRONCHODILATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESMOLOL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LABETALOL; METOPROLOL; NADOLOL; OXITROPIUM BROMIDE; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SALBUTAMOL; SOTALOL; THEOPHYLLINE; TIMOLOL;

ASTHMA; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; HEART INFARCTION; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0033501097     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006955     Document Type: Review

References (72)

1. Beta-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982;247:1707-1714.
2. Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
3. Hjalmarson A, Emfeldt D, Herlitz A, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C: Effect on mortality of metoprolol in acute myocardial infarction: A double-blind randomised trial. Lancet 1981;ii:823-827.
4. Committee on Management of Acute Myocardial Infarction: ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996;28:1328-1428.
5. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, Krumholz HM, Vogel RA: Quality of care for Medicare patients with acute myocardial infarction: A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-1514.
6. Brand DA, Newcomer LN, Freiburger A, Tian H: Cardiologists' practices compared with practice guidelines: Use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1423-1426.
7. Viskin S, Kitzis I, Lev E, Zak A, Heller K, Villa Y, Zajarias A, Laniado S, Belhassen B: Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-1332.
8. Barron HV, Viskin S, Lundstrom RJ, Swain BE, Truman AF, Wong CC, Selby JV: Beta-blocker dosages and mortality after myocardial infarction. Arch Intern Med 1998;158:449-453.
9. Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
10. McNeill RS: Effect of a beta adrenergic blocking agent, propranolol, on asthmatics. Lancet 1964;ii:1101-1102.
11. McNeill RS, Ingram CG: Effect of propranolol on ventilatory function. Am J Cardiol 1966;18: 473-475.
12. Raine JM, Palazzo MG, Kerr HH, Sleight P: Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. Br Med J 1981;282:548-549.
13. Williams IP, Millard FJC: Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980;35:160.
14. Harries AD: Beta blockade in asthma. Br Med J 1981;282:1321.
15. Fraunfelder FT, Barker AF: Respiratory effects of timolol. N Engl J Med 1984;311:1441.
16. Odeh M, Oliven A, Bassan H: Timolol eye-drop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991;32:97-98.
17. Wilcox PG, Ahmad D, Darke AC, Parsons J, Carruthers SG: Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther 1986;39:29-34.
18. Decalmer PBS, Chatterjee SS, Cruickshank JM, Benson MK, Sterling GM: Beta blockers and asthma. Br Heart J 1978;40:184-189.
19. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, National Institutes of Health, 1997, NIH Publ No. 97-4051.
20. NHLBI/WHO: Global Initiative for Asthma. Bethesda, National Institutes of Health, 1995, NIH Publ No. 95-3659.
21. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260:2088-2093.
22. Olsson G, Wikstrand J, Warnold I, Cats VM, McBoyle D, Herlitz J, Hjalmarson A, Sonenblick EH: Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32.
23. Hinstridge V, Speight TM: An overview of therapeutic interventions in myocardial infarction: Emphasis on secondary prevention. Drugs 1991;42(suppl2):8-20.
24. Boissel J-P, Leizorovicz A, Picolet H, Peyrieux J-C: Secondary prevention after high-risk acute myocardial infarction with low doses acebutolol. Am J Cardiol 1990;66:251-260.
25. Zaid G, Beall GN: Bronchial response to beta-adrenergic blockade. N Engl J Med 1966;275: 580-584.
26. Johnsson G, Svedmyr N, Thiringer G: Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate, and blood pressure in asthmatics. Eur J Clin Pharmacol 1975;8:175-180.
27. Skinner C, Gaddie J, Palmer KNV, Kerridge DF: Comparison of effect of metoprolol and propranolol on asthmatic airway obstruction. Br Med J 1976;i:540.
28. Anderson EG, Calcraft B, Jariwalla AG, Al-Zaihak M: Persistent asthma after treatment with beta blocking drugs. Br J Dis Chest 1979; 73:407-408.
29. Oh VMS, Kaye CM, Warrington SJ, Taylor EA, Wadsworth J: Studies of cardioselectivity and partial agonist activity in beta adrenoreceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise. Br J Clin Pharmacol 1978;5:107-120.
30. Clague H, Ahmad D, Carruthers SG: Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta blockade. Eur J Clin Pharmacol 1984;27:517-523.
31. Stewart WC, Garrison PM: Beta blocker-induced complications and the patient with glaucoma. Arch Intern Med 1998;158:221-226.
32. Singh BN, Whitlock RML, Comber RH, Williams FH, Harris EA: Effects of cardioselective beta adrenoreceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther 1976;19:493-501.
33. Thringcr B, Svedmyr N: Interaction of orally administered metoprolol, practolol and pro pranolol with isoprenaline in asthmatics. Eur J Clin Pharmacol 1976;10:163-170.
34. Formgren H: The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 1976;3:1007-1014.
35. Lofdahl CG, Svedmyr N: Cardioselectivity of atenolol and metoprolol: A study in asthmatic patients. Eur J Respir Dis 1981;62:396-404.
36. Lawrence DS, Sahay JN, Chatterjee SS, Cruickshank JM: Asthma and beta blockers. Eur J Clin Pharmacol 1982;22:501-509.
37. Mue S, Sasaki T, Shibahara S, Takahashi M, Ohmi T, Yamauchi K, Suzuki S, Hida W, Takishima T: Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients. Int J Clin Pharmacol Biopharm 1979; 17:346-350.
38. Lammers JW, Folgering HT, van Herwaarden CL: Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. J Cardiovasc Pharmacol 1986;8(suppl 11):S69-S73.
39. Abraham TA, Hasan FM, Fenster PE, Mercer FI: Effect of intravenous metoprolol on reversible obstructive airways disease. Clin Pharmacol Ther 1981;29:582-587.
40. Greefhorst AP, van Herwaarden CL: Comparative study of the ventilatory effects of three beta-1 selective blocking agents in asthmatic patients. Eur J Clin Pharmacol 1981;20:417-421.
41. Plosker GL, Clissold SP: Controlled release metoprolol formulations. Drugs 1992;43:382-414.
42. Ellis ME, Sahah JN, Chatterjee SS, Cruickshank JM, Ellis SH: Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol 1981;21:173-176.
43. Ruffin RE, McIntyre ELM, Latimer KM, Ward HE, Crockett AJ, Alpers JH: Assessment of beta adrenoceptor antagonists in asthmatic patients. Br J Clin Pharmacol 1982;13:325S-335S.
44. Benson MK, Berrill WT, Sterling GM, Chatterjee SS, Croxson RS, Cruickshank JM: Cardioselective and non-cardioselective beta blockers in reversible obstructive airways disease. Post-grad Med J 1977;53(suppl 3):143-148.
45. Vilsvik JS, Schaaning J: Effect of atenolol on ventilatory and cardiac function in asthma. Br Med J 1976;ii:453-455.
46. Astrom H: Comparison of the effects on airway conductance of a new selective beta adrenergic blocking drug, atenolol, and propranolol in asthmatic subjects. Scand J Respir Dis 1975; 56:292-296.
47. Boye NP, Vale JR: Effect in bronchial asthma of a new beta adrenergic blocking drug atenolol. Eur J Clin Pharmacol 1977;11:11-14.
48. Jackson SHD, Beevers DG: Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. Br J Clin Pharmacol 1983; 13:553-556.
49. van Zyl Al, Jennings AA, Bateman ED, Oie LH: Comparison of respiratory effects of two cardioselective beta blockers, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. Chest 1989;95:209-213.
50. Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steek J, Laddu A: Effects of esmolol on airway function in patients with asthma. J Clin Pharmacol 1986;26:169-174.
51. Kirshenbaum JM, Kloner RF, McGowan N, Antman EM: Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy. J Am Coll Cardiol 1988;12:773-780.
52. Mooss AN, Hilleman DE. Mohiuddin SM, Hunter CB: Safety esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta blocker therapy. Ann Pharmacother 1994;28:701-703.
53. Cockcroft DW: Management of acute severe asthma. Ann Allergy Asthma Immunol 1995; 75:83-89.
54. Ind PW, Dixon CMS, Fuller RW, Barnes PJ: Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 1989;139:1390-1394.
55. Macdonald AG, Ingram CG, McNeill RS: The effect of propranolol on airway resistance. Br J Anaesth 1967;39:919-926.
56. Grieco MH, Pierson RN: Mechanism of bronchoconstriction due to beta adrenergic blockade. J Allergy Clin Immunol 1971;48:143-152.
57. Langer I: The bronchoconstrictor action of propranolol aerosol in asthmatic subjects. J Physiol (Lond) 1967;190:41.
58. Giulekas D, Georgopoulos D, Papakosta D, Antoniadou H, Sortiropoulou E, Vamvalis C: Influence of pindolol on asthmatics and effect of bronchodilators. Respiration 1986;50:158-166.
59. Mattson K, Poppium H: Controlled study of the bronchoconstriction effect of pindolol administered intravenously or orally to patients with unstable asthma. Eur J Clin Pharmacol 1978;14:87-92.
60. Christensen CC, Boye NP. Erickson H, Hansen G: Influence of pindolol on respiratory function in 20 asthmatic patients. Eur J Clin Pharmacol 1978;13:9-12.
61. Lofdahl CG, Svedmyr K, Svedmyr N: Selectivity of bevantolol hydrochloride, a beta-1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy 1984;4:205-210.
62. Peterson CD, Leeder JS, Sterner S: Glucagon therapy for beta-bloeker overdose. Drug Intell Clin Pharm 1984;18:394-398.
63. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Am Coll Cardiol 1999;33: 598-604.
64. Ferrari R (ed): ACE inhibition and myocardial ischaemia - New challenge for the third millennium. Eur Heart J 1998;19(suppl J):J1-J60.
65. Andersson RG, Persson K: ACE inhibitors and their influence on inflammation, bronchial reactivity and cough. Eur Heart J 1994; 15(suppl C):52-56.
66. Kaufman J, Schmitt S, Barnard J, Busse W: Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma. Chest 1992;101:922-925.
67. Riska H, Stenius-Aarniala B, Sovijarvi AR: Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma. J Cardiovasc Pharmacol 1987; 10(suppl 10):S79-S81.
68. Semple PF, Herd GW: Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med 1986;296:86-88.
69. National Cholesterol Education Program Expert Panel: Second report on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1333-1345.
70. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R: Association between genetic polymorphisms of the beta: adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-3188.
71. 2 adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 1997;350:995-999.
72. Lima JJ, Thomason DB, Mohamed MHN, Eberle LV, Self TH, Johnson JA: Impact of genetic polymorphisms of the beta: adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999;65: 519-525.